News coverage about VIVUS (NASDAQ:VVUS) has been trending somewhat positive on Friday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. VIVUS earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.6991648344839 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
VVUS has been the topic of several recent research reports. Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, July 27th. ValuEngine lowered VIVUS from a “buy” rating to a “hold” rating in a report on Friday, September 1st.
Shares of VIVUS (NASDAQ VVUS) traded up 0.7658% on Friday, reaching $0.8553. The company’s stock had a trading volume of 687,724 shares. The company’s 50 day moving average price is $0.94 and its 200 day moving average price is $1.07. The company has a market cap of $90.50 million, a P/E ratio of 2.7590 and a beta of 0.96. VIVUS has a 12-month low of $0.84 and a 12-month high of $1.47.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-vivus-vvus-share-price.html.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.